Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients

Liver Transplantation

Volumn 20, Issue 6, 2014, Pages 655-663

  O'Leary, Jacqueline G ^a   Kaneku, Hugo ^b   Jennings, Linda ^a   Susskind, Brian M ^a   Terasaki, Paul I ^b,c   Klintmalm, Göran B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CYCLOSPORIN; DACLIZUMAB; DONOR SPECIFIC HUMAN LEUKOCYTE ANTIGEN ALLOANTIBODY; HLA ANTIBODY; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HLA ANTIGEN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DONOR; FEMALE; FLUORESCENCE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; BIOPSY; BLOOD; COMPLICATION; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

BIOLOGICAL MARKERS; BIOPSY; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897110309     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23854     Document Type: Article

References (37)

1. Gane E,. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28-S34.
2. Wiesner RH, Sorrell M, Villamil F,; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.
3. Carriõn JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
4. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
5. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599.
6. Lai JC, O'Leary JG, Trotter JF, Verna EC, Brown RS Jr, Stravitz RT, et al.; for Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012; 18: 532-538.
7. Biggins SW, Trotter J, Gralla J, Burton JR Jr, Bambha KM, Dodge J, et al. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 2013; 58: 969-976.
8. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
9. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003; 3: 1407-1412.
10. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
11. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740.
12. Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004; 77: 1834-1842.
13. Nair S, Eustace J, Thuluvath PJ,. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359: 287-293.
14. Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003; 9: 117-123.
15. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
16. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al.; for Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
17. O'Leary JG, Gebel HM, Ruiz R, Bray RA, Marr JD, Zhou XJ, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
18. O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB,. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
19. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI,. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
20. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
21. Takaya S, Duquesnoy R, Iwaki Y, Demetris J, Yagihashi A, Bronsther O, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (pt 1): 396-399.
22. O'Leary JG, Klintmalm GB,. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013; 18: 279-284.
23. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
24. Hughes MG Jr, Rosen HR,. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009; 15: 1395-1411.
25. Reed EF,. Mechanisms of action and effects of antibodies on the cells of the allograft. Hum Immunol 2012; 73: 1211-1212.
26. Musat AI, Pigott CM, Ellis TM, Agni RM, Leverson GE, Powell AJ, et al. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132-1141.
27. Leonard GR, Shike H, Uemura T, Gaspari JL, Ruggiero FM, Shah RA, et al. Liver transplantation with a strongly positive crossmatch: case study and literature review. Liver Transpl 2013; 19: 1001-1010.
28. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
29. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V,. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
30. Yamada H, Kondou H, Kimura T, Ikeda K, Tachibana M, Hasegawa Y, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012; 16: 858-865.
31. Demetris AJ, Isse K,. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18: 345-353.
32. Demetris AJ, Murase N, Nakamura K, Iwaki Y, Yagihashi A, Valdivia L, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
33. O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant. DOI: 10.1111/ajt.12667.
34. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
35. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
36. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK,. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
37. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.